Found 62 of ec50 data for polymerid = 253,9837,10170 TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 0.300nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 0.460nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 0.75nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 0.75nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 0.75nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 0.75nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 0.75nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 0.75nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 0.75nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 0.950nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 1.48nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 16.7nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
